Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV

deFilippi, Christopher; McCallum, Sara; Zanni, Markella V.; Fitch, Kathleen V.; Diggs, Marissa R.; Bloomfield, Gerald S.; Fichtenbaum, Carl J.; Aberg, Judith A.; Malvestutto, Carlos D.; Pinto-Martinez, Adriana; Stapleton, Ann; Duggan, Joan; Robbins, Gregory K.; Taron, Jana; Karady, Julia; Foldyna, Borek; Lu, Michael T.; Ribaudo, Heather J.; Douglas, Pamela S.; Grinspoon, Steven K.

doi:10.1016/j.jacadv.2024.101206

JACC: Advances

2024

DOI: 10.1016/j.jacadv.2024.101206

|View full text |Cite

Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV

Christopher deFilippi,

Sara McCallum,

Markella V. Zanni

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Predicting Incident CVD Risk With High-Sensitivity Cardiac Troponin

McEvoy,

Mangan

2024

JACC: Advances

View full text Add to dashboard Cite

Predicting Incident CVD Risk With High-Sensitivity Cardiac Troponin

McEvoy,

Mangan

2024

JACC: Advances

View full text Add to dashboard Cite

Reducing Cardiovascular Risk in HIV: The Unseen Impact of Visceral Fat

Roberts

2024

AMJ Microbiology and Infectious Diseases

View full text Add to dashboard Cite

While modern antiretroviral therapy (ART) for people with HIV (PWH) increases life expectancy, there is still an increased risk of developing cardiovascular disease (CVD) in this population. As one factor associated with this increased risk is excess visceral abdominal fat (EVAF), the Visceral Adiposity Measurement and Observations Study (VAMOS) aimed to assess the impact of EVAF on CVD risk in PWH taking modern ART. Participants were grouped according to visceral adipose tissue (VAT) surface area <130 cm2 (non-EVAF group) or ≥130 cm2 (EVAF group), quantified by CT scan. Findings presented at IDWeek 2024 revealed significant differences between EVAF and non-EVAF groups in 10-year atherosclerotic CVD (ASCVD) risk score, as well as many of their individual components. VAMOS also showed correlations between increasing VAT surface area and increasing 10-year ASCVD risk score and insulin resistance measures. Accordingly, VAT may represent a targetable factor to reduce ASCVD risk. Also shown was an inverse relationship between growth hormone (GH) levels and VAT surface area. As GH reductions related to obesity are associated with elevated CVD risk, increasing GH levels may consequently reduce ASCVD risk score. Analysis of two Phase III trials of the GH-releasing hormone (GHRH) analogue tesamorelin, which can significantly reduce VAT in PWH, was also presented at IDWeek 2024. A significant overall trend in 10-year ASCVD risk score reduction was shown in tesamorelin-treated participants, around half of which were already taking lipid lowering therapies. This suggests a benefit of targeting and reducing EVAF to further impact ASCVD risk.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV

Cited by 2 publications

References 29 publications

Predicting Incident CVD Risk With High-Sensitivity Cardiac Troponin

Predicting Incident CVD Risk With High-Sensitivity Cardiac Troponin

Reducing Cardiovascular Risk in HIV: The Unseen Impact of Visceral Fat

Contact Info

Product

Resources

About